Dr Agarwal’s Eye Hospital Ltd Q3 FY26 – ₹451 Cr Sales, 32% OPM, 29.5% ROE, and a Merger That Wants to Swallow Itself
1. At a Glance – Blink and You’ll Miss the Growth
₹2,260 crore market cap. Stock at ₹4,677. P/E of 32.4. ROE flirting with 30%. OPM chilling at ~32% like it owns the place. In Q3 FY26, revenue clocked ₹116 crore (+22% YoY) while PAT jumped 66% YoY to ₹17.3 crore. This is not a sleepy regional eye clinic anymore — this is a cataract cash machine with an MBA.
But wait, there’s drama. Promoters have pledged ~29% of their stake. Debt stands at ₹335 crore. And just when investors were getting comfortable tracking AEHL, management said: “Relax, we’re merging you into the parent.”
So what exactly is Dr Agarwal’s Eye Hospital Ltd? A clean compounding healthcare story? Or a well-lit operating theatre hiding balance-sheet sutures? Let’s scrub in.
2. Introduction – From Eye Camp to Eye Empire
Founded in 1994, Dr Agarwal’s Eye Hospital Ltd (AEHL) started with a simple idea: fix eyesight at scale in Tamil Nadu. Fast forward three decades, and the company operates 63 facilities, employs 200+ doctors, and serves ~5.9 lakh patients annually, performing ~62,000 surgeries in FY25 alone.
Cataract is the hero here — boring, repetitive, and insanely profitable. Like a Bollywood remake franchise, but for eyeballs. Add refractive surgeries, glaucoma, retina, LASIK, optics, diagnostics, and suddenly you have a vertically integrated ophthalmology assembly line.
AEHL is also a subsidiary of Dr Agarwal’s Health Care Ltd (DAHCL), which owns ~72%. And that’s important — because the parent is now planning to merge AEHL into itself, effectively ending AEHL’s solo listed life by FY27.
So before this stock becomes a memory, let’s understand whether it deserved the premium it enjoyed.
3. Business Model – WTF Do They Even Do?
Think of AEHL as a hub-and-spoke eye factory.
Step 1: Vision Centres
Small clinics, low capex, high footfall. These act as funnels. Patients come in for checkups, diagnostics, specs, consultations.
Step 2: Surgical Centres
Serious stuff happens here. Cataract surgeries, retina work, LASIK. This is where margins explode.
Step 3: Opticals + Pharmacy
Because why stop at surgery margins when you can also sell lenses, specs, and eye drops?
Revenue mix FY25:
Surgeries: 63.9%
Opticals & pharma: 23.2%
Consultation & diagnostics: 12.8%
This model works because:
Cataract volumes are massive and predictable
Doctors are semi-fixed costs
Equipment gets sweated hard
Working capital cycle is negative (yes, patients pay faster than suppliers)
Simple question: if India is aging and screens are everywhere, does this business ever run out of customers?
4. Financials Overview – The Numbers That Do the Talking
